RYZ101 vs Lutathera in 2L+ GEP-NETs — PatSnap Eureka
RYZ101 vs Lutathera in 2L+ GEP-NETs: The Next Radioligand Therapy Showdown
BMS Radiopharma's RYZ101 ([177Lu]Lu-DOTA-ZB102) is advancing through the ACTION-1 Phase III trial, challenging Lutathera's established standard of care in SSTR2-positive gastroenteropancreatic neuroendocrine tumors. Understand the mechanism, IP, and clinical landscape with PatSnap Eureka.
How SSTR2-Targeted Radioligand Therapy Works in GEP-NETs
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a heterogeneous and historically underserved oncology segment where somatostatin receptor (SSTR2)-targeted radioligand therapy has emerged as a validated therapeutic strategy. Neuroendocrine tumor cells overexpress SSTR2 on their surface, providing a targetable anchor for radiolabelled peptide conjugates that deliver localised beta-radiation directly to the tumor.
The approval of Lutathera (lutetium-177 DOTATATE) established [177Lu]Lu-DOTATATE as a standard of care in progressive, SSTR-positive midgut NETs. This approval created a defined benchmark against which next-generation radiopharmaceuticals — including RYZ101 ([177Lu]Lu-DOTA-ZB102), developed under the Bristol Myers Squibb Radiopharma platform — are now being evaluated in Phase III settings.
Both agents use lutetium-177 as the radioactive payload, but differ in their targeting vector and chelation chemistry. Lutathera uses DOTATATE as the somatostatin analogue vector, while RYZ101 employs the investigational DOTA-ZB102 vector. The upstream IP landscape spans radiochemistry, chelation approaches, and SSTR-targeting vector design — dimensions now being actively contested by key assignees including BMS and Novartis.
For a comprehensive review of radioligand therapy mechanisms, the European Medicines Agency and FDA have both published detailed assessment reports on lutetium-177 DOTATATE. The ClinicalTrials.gov registry provides the full ACTION-1 protocol for researchers requiring endpoint-level detail.
RYZ101 vs Lutathera: Clinical and IP Landscape Data
Visualising the key dimensions that define the competitive radioligand therapy landscape for SSTR2-positive GEP-NETs, from mechanism to Phase III trial design.
RYZ101 vs Lutathera: Key Mechanism Dimensions
Both agents share lutetium-177 as the radioactive payload but diverge in targeting vector and clinical development stage.
RLT IP Landscape: Key Search Dimensions
Three critical IP dimensions define the competitive radioligand therapy patent landscape for SSTR2-targeted GEP-NET therapies.
ACTION-1 Phase III: What the Trial Design Signals
The ACTION-1 Phase III trial for RYZ101 in 2L+ GEP-NETs covers four critical dimensions that define the competitive and regulatory landscape for next-generation radioligand therapy.
Phase III Evaluation in 2L+ SSTR-Positive GEP-NETs
ACTION-1 evaluates RYZ101 ([177Lu]Lu-DOTA-ZB102) in patients with gastroenteropancreatic neuroendocrine tumors who are SSTR-positive and have received at least one prior line of therapy. The trial is designed to assess RYZ101 against the Lutathera standard of care established by the NETTER-1 Phase III programme.
2L+ Patient PopulationPatient Stratification in SSTR-Positive Tumors
Key trial design considerations include endpoint selection and patient stratification in SSTR-positive GEP-NETs. The competitive IP and translational landscape spans both upstream radiochemistry and chelation IP, and downstream clinical translation signals including how patients are selected and stratified for SSTR2-targeted therapy.
SSTR2 StratificationBMS Radiopharma: From RayzeBio Acquisition to Phase III
RYZ101 was originally developed under RayzeBio before Bristol Myers Squibb's acquisition brought it under the BMS Radiopharma platform. The assignee IP landscape now involves BMS as the primary patent holder for RYZ101-related radiopharmaceutical innovations, competing with Novartis's established DOTATATE IP portfolio in the SSTR-targeting space. Track this landscape on PatSnap Analytics.
BMS Radiopharma AssigneeCombination RLT: The Next IP Frontier
Beyond head-to-head comparison, the RLT IP landscape encompasses combination radioligand therapy approaches — pairing SSTR2-targeted agents with checkpoint inhibitors, targeted therapies, or other radiopharmaceuticals. These combination strategies represent an emerging area of patent activity and clinical investigation in the GEP-NET space, as tracked through PatSnap's innovation intelligence platform.
Combination RLT IPKey IP and Translational Signals for 2L+ GEP-NET RLT
The competitive radioligand therapy landscape for gastroenteropancreatic neuroendocrine tumors spans upstream radiochemistry IP through to downstream clinical translation — four strategic dimensions define the competitive positioning of RYZ101 and Lutathera.
Upstream Radiochemistry & Chelation IP
The foundational IP layer covers lutetium-177 radiochemistry, DOTA chelation chemistry, and the synthesis of radiolabelled peptide conjugates. Both BMS Radiopharma (DOTA-ZB102) and Novartis (DOTATATE) hold differentiated positions in chelation and vector IP — a critical upstream battleground for next-generation RLT development in SSTR-positive GEP-NETs.
SSTR-Targeting Vector Design
Somatostatin receptor targeting vectors — the peptide or peptidomimetic components that direct the lutetium-177 payload to SSTR2-expressing tumor cells — represent a key area of IP differentiation. RYZ101's DOTA-ZB102 vector is the investigational counterpart to Lutathera's established DOTATATE, with downstream implications for receptor binding affinity, tumor uptake, and normal tissue dosimetry.
RYZ101 vs Lutathera: Full Competitive Profile
A structured comparison of the key development, mechanism, and IP dimensions across both SSTR2-targeted radioligand therapy agents in the GEP-NET landscape.
| Dimension | RYZ101 (BMS Radiopharma) | Lutathera (Novartis) |
|---|---|---|
| INN / Asset Name | [177Lu]Lu-DOTA-ZB102 | [177Lu]Lu-DOTATATE SoC |
| Radioisotope | Lutetium-177 | Lutetium-177 |
| Targeting Vector | DOTA-ZB102 (investigational) | DOTATATE (established) IP Leader |
| Mechanism | SSTR2-targeted radioligand therapy | SSTR2-targeted radioligand therapy |
| Clinical Stage | Phase III — ACTION-1 | FDA Approved (2018) Approved |
| Target Population | 2L+ SSTR-positive GEP-NETs | Progressive SSTR+ midgut NETs |
| Primary Assignee | Bristol Myers Squibb Radiopharma (formerly RayzeBio) | Novartis (Advanced Accelerator Applications) |
Need a Fully Cited RLT Patent Intelligence Report?
PatSnap Eureka searches across SSTR2 targeting, lutetium-177 radiochemistry, and GEP-NET clinical signals — all in one query.
RYZ101 vs Lutathera in 2L+ GEP-NETs — key questions answered
RYZ101 ([177Lu]Lu-DOTA-ZB102) is a next-generation radioligand therapy developed under the Bristol Myers Squibb Radiopharma platform, targeting somatostatin receptor 2 (SSTR2) in GEP-NETs. Lutathera ([177Lu]Lu-DOTATATE) was the first approved SSTR2-targeted radioligand therapy and established the standard of care in progressive, SSTR-positive midgut NETs. RYZ101 is being evaluated in the ACTION-1 Phase III trial in the 2L+ setting against this established benchmark.
ACTION-1 is the Phase III clinical trial evaluating RYZ101 ([177Lu]Lu-DOTA-ZB102) in patients with second-line or later (2L+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are SSTR-positive. The trial is being conducted under the Bristol Myers Squibb Radiopharma platform and is designed to assess RYZ101 against the Lutathera standard of care.
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous and historically underserved oncology segment. The 2L+ (second-line and beyond) setting refers to patients who have already received at least one prior line of therapy. This is a critical unmet need area where SSTR2-targeted radioligand therapy has emerged as a validated therapeutic strategy.
SSTR2-targeted radioligand therapy (RLT) is a therapeutic approach that uses molecules targeting somatostatin receptor 2 (SSTR2), which is overexpressed on neuroendocrine tumor cells, to deliver a radioactive payload (such as lutetium-177) directly to the tumor. The approval of Lutathera (lutetium-177 DOTATATE) validated this strategy as a standard of care in progressive, SSTR-positive midgut NETs.
The competitive IP and translational landscape for 2L+ GEP-NET treatment involves key assignees including Bristol Myers Squibb Radiopharma (developing RYZ101, formerly under RayzeBio) and Novartis (the originator of Lutathera/lutetium DOTATATE). The landscape spans upstream IP in radiochemistry, chelation, and SSTR-targeting vectors, as well as downstream clinical translation signals including trial design, endpoint selection, and patient stratification in SSTR-positive GEP-NETs.
Lutetium-177 is a beta-emitting radioisotope used in radioligand therapy. It is chelated to a targeting vector (such as DOTATATE or DOTA-ZB102) that binds to somatostatin receptors overexpressed on neuroendocrine tumor cells. Once bound, the lutetium-177 delivers localised radiation to the tumor. Both Lutathera and RYZ101 use lutetium-177 as the radioactive payload, with differences in the targeting vector and chelation chemistry.
Still have questions? Let PatSnap Eureka search the RLT patent and literature landscape for you.
Ask Eureka About RYZ101 & GEP-NETsAccelerate Your Radioligand Therapy Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map SSTR2 IP, track RYZ101 and Lutathera filings, and navigate the 2L+ GEP-NET competitive landscape.
References
- U.S. Food & Drug Administration (FDA) — Lutathera ([177Lu]Lu-DOTATATE) approval documentation and prescribing information, 2018.
- European Medicines Agency (EMA) — Lutathera European Public Assessment Report (EPAR) and CHMP scientific assessment of lutetium-177 DOTATATE.
- ClinicalTrials.gov — ACTION-1 Phase III trial registration: RYZ101 ([177Lu]Lu-DOTA-ZB102) in 2L+ SSTR-positive GEP-NETs. NCT registry, Bristol Myers Squibb Radiopharma.
- Novartis / Advanced Accelerator Applications — NETTER-1 Phase III trial results and Lutathera commercial programme publications.
- PatSnap Life Sciences Intelligence — Radioligand therapy IP landscape analysis, SSTR2-targeting vector patent activity, and BMS Radiopharma assignee monitoring.
- PatSnap Analytics — Competitive intelligence platform for pharmaceutical patent landscape analysis including GEP-NET radioligand therapy.
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. The structured analysis framework and IP dimension mapping are derived from PatSnap Eureka's analytical methodology for pharmaceutical competitive intelligence.
PatSnap Eureka searches patents and research to answer instantly.